Alzheimer’s Disease

Aug 20, 2020

FDA rejects BioMarin's gene therapy and Gilead's filgotinib over concerns The FDA refused to approve BioMarin's hemophilia A gene therapy valoctocogene roxaparvovec. The U.S. regulator that had earlier told there was no requirement of an AdComm for the drug, aka, valrox, has issued a complete response (CRL) lett...

Aug 13, 2020

Researchers call out Gilead over the diversity of remdesivir trials Researchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an evaluation of Gilead’s remdesivir clinical trials, which found the studies that flunked to offer an equal representation of Bla...

Jul 30, 2020

Roche bets USD 120 Million on UCB's anti-tau Alzheimer's antibody The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB's anti-tau antibody development. If everything goes according to plan, milestone payments and royalties could bring the deal's total near to USD 2 billion. Th...

Jul 02, 2020

Amylyx Pharmaceuticals grabs USD 30 Million  Amylyx Pharmaceuticals has grabbed USD 30 million boosts after posting positive data, which showed it could help decrease amyotrophic lateral sclerosis (ALS). AMX0035, which is its leading candidate, is being tested in degenerative ALS and Alzheimer’s disease....

Jun 03, 2020

Alzheimer’s is a brain disease, associated with the degeneration of brain cells. It is an irreversible and progressive disease that generally affects people aged above 65 years but in very rare cases, early-onset has also been noticed in the late ’40s. The AD affects memory, reasoning and cognitive skills of the pe...

Jan 29, 2020

The 21st century has been a remarkable century for humankind, as a lot of innovation, research and development has taken place in the field of healthcare, due to which we have been able to increase the overall lifespan of the human beings.  However, the central question is, are we able to increase the healt...

Jan 23, 2020

Horizon Therapeutics has become the first company to receive the regulatory approval of its drug Tepezza for the cure of Thyroid Eye Tepezza (teprotumumab-trbw) is the first-ever treatment approved for thyroid eye is a progressive autoimmune disorder hampering the ability of vision. The drug was approved under P...

Nov 29, 2019

Alzheimer's Disease Market Infographic It's is the end of Alzheimer's Awareness Month, but our hope for a cure for this disease will not end. They may not remember us, but we need to remember that Alzheimer's battle is not theirs alone, but all of ours.

Nov 28, 2019

Sanofi’s Toujeo has received FDA recommendation for its expanded use in Type 1 Diabetes. Toujeo is an insulin glargine injection to control the highs and lows of blood sugar in the body. Indicated to be used in adults and paediatric patients of age six and older. Earlier, the injection was considered suitab...

May 02, 2019

EISAI now solely responsible for lemborexant Eisai today announced that its U.S. subsidiary has bought out  Purdue Pharma L.P.’s rights in the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multip...